Obssessive Compulsive Disorder. Obsessive-compulsive disorder
Conditions
Interventions
Intervention 1: Intervention group: Patients of the intervention group are treated with pregabalin drug of Iran Daru Company. The starting dose is 75 mg at night, and if the patient tolerates it, in t
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: Age between 18 and 59 years Definite diagnosis of obsessive-compulsive disorder, which is diagnosed by a specialist psychiatrist using the criteria of the revised edition of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V TR) Before the beginning of the study, they have been treated with SRIs with a fixed and appropriate dose for at least 12 weeks. YBOCS score higher than 13 (as considered as incomplete response or resistance to treatment.)
Exclusion criteria
Exclusion criteria: Pregnancy Significant medical illness Diagnosis of psychotic or bipolar disorders Starting or changing the dosage of other psychiatric medication in the last 3 months Patients undergoing psychotherapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Obsession or compulsion severity. Timepoint: At the beginning of taking pregabalin or placebo and after 3 months of use. Method of measurement: Yale-Brown Obsessive Compulsive Scale.;Anxiety severity. Timepoint: At the beginning of taking pregabalin or placebo and after 3 months of use. Method of measurement: HADS questionnaire (Hospital Anxiety Depression Scale). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Shahmoradi
Arak University of Medical Sciences
Outcome results
None listed